News

The open-label, multi-center, randomized study in chronic kidney disease (CKD) patients on hemodialysis demonstrated a statistically significant achievement of all the primary and secondary endpoints, the company said.

Preliminary results from the Phase I study, conducted to assess the safety and biological activity of the anti-IL-5 receptor MAb, suggest that the antibody-dependent cellular cytotoxicity (ADCC) enhanced

Targacept’s drug, AZD3480, acts selectively on neuronal nicotinic receptors and has been evaluated in 12 clinical trials in approximately 540 subjects. In a previous Phase IIb trial in

A fast-track designation speeds up the review process and is generally given to drugs that address an unmet need for serious or life-threatening conditions. Neurochem said that it

Inovio’s DNA delivery systems are designed with the aim of enhancing the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers. The collaboration with the National

Results from the trial, presented at the fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, demonstrate that the drug, INCB9471, provided a significant decline in

However, earnings per share for the period dropped 29% from $1.08 to $1.53. The company said that key drugs such as Cymbalta and Alimta had boosted sales in

The study was designed to determine the effects of vaccination with HspE7 in women with high-grade cervical intraepithelial neoplasia (CIN II/III), a precursor to cervical cancer. The results

As of July 20, 2007, the company closed recruitment at 638 patients. The patient population is made up of 228 Canadian patients, 294 patients from Germany and 116